Stock Information
Corcept Therapeutics Inc (CORT)
Ticker Symbol: CORT
Exchange: NASDAQ
Sector: Pharmaceuticals
Market Cap: $4,910.22 mil
Piotroski score: 6
PE Ratio: 54.1028
EPS (TTM): 0.8303
Revenue (TTM): $6.34 M
Dividend Yield: N/A%
ROE: 15.34%
Latest News
-
Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $88
Fri, May 1, 2026 1:36 PM
-
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
Fri, May 1, 2026 10:52 AM
-
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Fri, May 1, 2026 5:31 AM
-
Transcript : Corcept Therapeutics Incorporated, Q1 2026 Earnings Call, Apr 30, 2026
Fri, May 1, 2026 5:05 AM
-
Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum
Thu, Apr 30, 2026 11:22 PM
-
Corcept Therapeutics Q1 2026 Earnings Call Transcript
Thu, Apr 30, 2026 5:46 PM
-
Corcept: Q1 Earnings Snapshot
Thu, Apr 30, 2026 5:24 PM
-
Corcept Therapeutics Announces Its Phase 2 DAZALS Trial Of Cortisol Modulator Dazucorilant To Treat Amyotrophic Lateral Sclerosis Failed To Meet Primary Endpoint
Thu, Apr 30, 2026 4:20 PM
-
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Thu, Apr 30, 2026 4:10 PM
-
Corcept Therapeutics Raises FY2026 Sales Guidance from $900.000M-$1.000B to $950.000M-$1.050B vs $941.180M Est
Thu, Apr 30, 2026 4:08 PM
Key Financials
Financial data not available
